Index
Module 4 • Quality & Safety
Protocol Development & Quality Improvement
75%
Data Tables
Protocol Development & Quality Improvement
Jaime Robenolt Gray ~2 min read Module 4 of 20
33
/ 44

Protocol Development and Quality Improvement

Provide data for QA or research initiatives.

Accreditation purposes

Promotional reasons

Financial impact can be analyzed and used to justify time spent in that area.

8

Reports

Statistical interpretations of services

Satisfaction surveys of their services

Risk reduction

d.Peer review

Publication

Return on investment data

Future initiatives

9
Pharmacotherapeutic intervention data should be presented and emphasized at as many committee

opportunities as possible – this increases the visibility and corroborates the importance of the pharmacy

department and the critical care pharmacy services. Box 2 lists examples of pharmacotherapeutic

interventions that can be reported. Pharmacotherapeutic intervention data should be presented to the

following:

ICU committee

Subcommittees of P&T including ICU, neurology, pediatrics, anticoagulation, or other

subspecialty committees.

P&T committee

QA committee

d.Medication use review committee

Formulary committee

Medication safety committee

Antimicrobial stewardship committee

Medical executive committee – Engages with potential expansion of pharmacy services or cost

avoidance

10Select a regular cadence for which pharmacotherapeutic intervention data will be presented, such as

monthly or quarterly (Figure 2). These data should include the type of intervention (Figure 3) and both

the raw drug cost savings derived from changing to less expensive drugs and the outcome cost savings

such as preventing an adverse event and decreasing the LOS (Figure 4).

Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 32 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube